Candel Therapeutics(CADL) - 2022 Q4 - Annual Report

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40629 | --- | --- | --- | |-----------------------------------------------------|-------------------|-------------------------------------------------------| | | | | | Title of each class | Trading Symbol(s) | Name ...